StockNews.com Initiates Coverage on TherapeuticsMD (NASDAQ:TXMD)

Analysts at StockNews.com assumed coverage on shares of TherapeuticsMD (NASDAQ:TXMD) in a report released on Monday. The brokerage set a “hold” rating on the stock.

TherapeuticsMD Stock Performance

Shares of TXMD stock opened at $1.23 on Monday. The business has a 50-day moving average of $1.50 and a 200 day moving average of $1.71. TherapeuticsMD has a 1-year low of $1.15 and a 1-year high of $2.75.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in TherapeuticsMD stock. Clearline Capital LP lifted its position in TherapeuticsMD, Inc. (NASDAQ:TXMD) by 18.9% in the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 636,622 shares of the company’s stock after acquiring an additional 101,282 shares during the period. Clearline Capital LP owned 5.52% of TherapeuticsMD worth $1,025,000 as of its most recent SEC filing. 30.74% of the stock is owned by hedge funds and other institutional investors.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.